Athenex Announces Oral Paclitaxel and Encequidar had a Significantly Higher Response Rate Over IV Paclitaxel in a Phase III Pivotal Study in Metastatic Breast Cancer

A recently published Phase III Trial by Athenex, Inc. showed that oral paclitaxel in combination with encequidar was superior to IV paclitaxel for Overall Response Rate in Metastatic Breast Cancer. Patients in the oral combination group also had less incidence of neuropathy than the intravenous group.

Victoria has blogged 1630 posts